Tenecteplase Versus Alteplase For Stroke Thrombolysis Evaluation (TASTE) Trial
Funder
National Health and Medical Research Council
Funding Amount
$4,180,030.00
Summary
Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation (TASTE) is an Australian-led international randomised trial designed to generate practice-changing evidence by translating the advanced imaging treatment selection approach used in our previous pilot studies. TASTE aims to confirm the superiority of the new-generation clot-dissolving agent, tenecteplase, over the standard agent, alteplase, in the broad group of stroke patients eligible for acute clot-dissolving treatment.
Short Duration Hypothermia To Prevent Subsequent Intracranial Pressure Rise.
Funder
National Health and Medical Research Council
Funding Amount
$436,453.00
Summary
Elevated brain pressure after stroke or other forms of brain injury can cause further injury and death. Body cooling to 32-33 C (hypothermia) for 12-24 hours saves lives after some forms of brain injury, but may have major side effects. We found that 2 hours hypothermia has a long-lasting effect preventing pressure elevation. We will determine the best temperature and duration of hypothermia in a stroke model and use imaging to confirm findings in patients, with a view to later human trials.
EXTEND-IA Randomized Trial Of Intra-arterial Clot Retrieval In Ischemic Stroke
Funder
National Health and Medical Research Council
Funding Amount
$764,534.00
Summary
Most strokes are caused by a blocked blood vessel in the brain. Current treatments to dissolve the blockage improve recovery for many patients but often fail to unblock larger brain arteries. The EXTEND-IA trial will use advanced brain imaging to identify patients who have the most to gain if the blocked artery can be re-opened. The trial will test whether a new minimally invasive clot removal procedure performed after standard clot-dissolving treatment improves recovery after stroke.